New Treatment Trial welcomes participants: Novartis AFQ056 We are thrilled to report that a large scale Fragile X clinical trial of an experimental new drug from Novartis has begun. Novartis AFQ056 is an mGluR5 antagonist - a compound which has been shown to reverse signs of Fragile X in animal models. The current double-blind, placebo controlled trial requires 9 office visits over 20 weeks. Three US sites - Chicago, Phoenix, and Houston - are recruiting adults aged 18-40 with Fragile X, and more sites will follow. Details here In addition, another mGluR5 antagonist - Roche's compound RO4917523 - is also in trials and participants are welcome. Details here
Happy New Year and Thank You!
We have met Doris Buffett's Challenge! Thanks to all of you who have supported FRAXA we have raised $500,000 since last spring and Doris Buffett's Sunshine Lady Foundation will match it! 3800 individuals, companies, and foundations donated to FRAXA in 2010, for a total of over $1.2 million - slightly more than was given the previous year. All of it will go to research to find a cure for Fragile X. Thank you all!! | |
Attention Scientists: FRAXA Research
Grant & Fellowship Applications due 2/1/11 FRAXA's goal is to bring enhanced treatments to families as quickly as possible, so all applications must pass through the filter of translational relevance. 2011 priorities and application details at fraxa.org
FRAXA Investigators Meeting September 18-21, 2011 Southbridge Hotel and Conference Center in Southbridge, MA Pursuing Pathways to Treatment details at fraxa.org |
Post a Comment